In a groundbreaking advancement for targeted drug delivery, an international team of scientists has successfully combined asymmetric-flow field-flow fractionation (AF4) with small-angle neutron scattering (SANS) for the first time. This novel approach, demonstrated on the Institut Laue-Langevin’s D11 instrument, allows unprecedented insight into the structural intricacies of lipid-based nanoparticles designed for efficient therapeutic delivery.
Targeted drug delivery relies heavily on nanoparticles to transport medication directly to diseased cells or specific organs, minimizing side effects and boosting treatment efficacy. Key factors influencing delivery success include the nanoparticle’s size, shape, internal organization, and batch uniformity. Traditional characterization methods often fall short in providing comprehensive nanoscale detail, especially about internal structures, essential for understanding how drugs are encapsulated and released.
AF4 is widely used to separate particles by size in solution, facilitating determination of size distributions. However, it does not reveal much about shape or inner architecture. Previously, AF4 was combined with small-angle X-ray scattering (SAXS) to probe particle morphology. The latest breakthrough enhances this capability by integrating SANS—leveraging the unique interaction of neutrons with matter, particularly their sensitivity to hydrogen and deuterium atoms. This contrast mechanism enables researchers to distinguish specific components inside nanoparticles by selectively substituting hydrogen with deuterium, a feat challenging for X-ray methods alone.
The research team utilized AF4 coupled simultaneously to multi-angle light scattering and SANS, allowing simultaneous fractionation and detailed scattering analysis. This multidimensional data gives not only size and shape information but also reveals the homogeneity of internal structures and spatial location of drug molecules within nanoparticles at sub-10-nanometer resolution. These insights are vital for optimizing nanoparticle design for controlled drug release and stability.
One major experimental hurdle was the dilution of samples inherent to AF4 fractionation, which weakens scattering signals and can lengthen experiments. The team introduced an innovative compensation technique that selectively focused detection on nanoparticle-enriched fractions, enhancing measurement efficiency and accuracy without compromising sample integrity.
Prof. Albena Lederer of the Leibniz Institute for Polymer Research Dresden highlights the significance: “Coupling AF4 with SANS represents a leap forward in nanoparticle characterization, enabling extraction of complementary information from minute sample amounts. This multidetection approach is poised to revolutionize biomedical polymer research and guide next-generation drug delivery system design.”
As targeted therapeutics become more sophisticated, precise characterization of delivery vehicles is paramount. The demonstrated AF4-SANS platform opens new avenues for biomedical research using neutron scattering, offering unparalleled detail that can drive innovations in nanomedicine and ultimately improve patient outcomes.
Subject of Research: Not applicable
Article Title: Structural Profiling of Lipid Nanoparticles at Sub-10 nm Resolution via AF4 Coupled Online to SAXS and SANS
News Publication Date: 30-Mar-2026
Web References: http://dx.doi.org/10.1002/smtd.70639
Image Credits: Small Methods (2026)
Keywords: Drug delivery systems, Nanomaterials, Pharmaceuticals, Neutrons
